source
- EMA launches consultation to streamline nonclinical development for life-threatening diseasesEMA announced a public consultation on proposals to accelerate the nonclinical phase of drug development for diseases that are severely debilitating or life‑threatening. The agency aims to reduce…
- Lilly beats forecasts while Novo Nordisk misses sales and trial targetsEli Lilly reported second-quarter revenue of nearly $23 billion, up 48% year-over-year, easily surpassing analysts’ $20.6 billion estimate. The boost came from continued strength of its tirzepatide…